Cutaneous leishmaniasis: The prospects for a killed vaccine

C. L. Greenblatt*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Scopus citations

Abstract

Of the various protozoal diseases for which vaccines are under development, cutaneous leishmaniasis (CL), in spite o f its chronic nature, may provide the best candidate for success. Stringent experimental models are available for both new and old world CL, human studies have been conducted for several years, and there is now considerable experience in using both attenuated and killed vaccines. In this article, Chuck Greenblatt discusses this experience, showing how it has led to current WHO-TDR plans for field trials of killed vaccines followed by virulent challenge (as used in Iran in the practice of 'leishmanization').

Original languageEnglish
Pages (from-to)53-54
Number of pages2
JournalParasitology Today
Volume4
Issue number2
DOIs
StatePublished - Feb 1988

Fingerprint

Dive into the research topics of 'Cutaneous leishmaniasis: The prospects for a killed vaccine'. Together they form a unique fingerprint.

Cite this